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Significance Statement
Administration of the hormone ghrelin has been shown to increase alcohol craving and drinking. Therefore, the ghrelin system
is being studied as a potential target to develop novel medications to treat alcohol use disorder (AUD). Both ghrelin and alcohol
interact with a variety of endocrine pathways, especially those related to appetite, metabolism, and stress. To better understand
the complex interplay between ghrelin and other hormones in the context of alcohol use, the present study examined neuroendocrine response to a supraphysiological challenge with exogenous ghrelin, combined with alcohol, in a clinically relevant
sample of heavy-drinking individuals with AUD. Results were consistent across 2 experimental alcohol administration paradigms and found a number of endocrine changes in response to exogenous ghrelin administration. This study provides a comprehensive picture of neuroendocrine response to ghrelin plus alcohol and provides a deeper insight into the interplay between
ghrelin and appetitive, metabolic, and stress-related hormones in the context of alcohol use.

Abstract

Key Words: Ghrelin, alcohol, neuroendocrine, metabolism, stress

Introduction
Alcohol is the most commonly used addictive drug worldwide,
and alcohol use disorder (AUD) represents a major global public
health concern (Rehm et al., 2018). Despite the high prevalence
of AUD and considerable medical, psychosocial, and economic
burden associated with the disease (Grant et al., 2016), treatment options, including medications, are limited in number
and efficacy (Jonas et al., 2014). Therefore, there is a critical
need to increase the armamentarium of pharmacotherapies
for AUD (Farokhnia et al., 2019a). While most of the research
in this regard has focused on central neurobiological mechanisms involved in addictive behaviors, there is growing interest
in understanding the role of peripheral/modulatory pathways
(e.g., endocrine system, immune factors, gut microbiome) and
their potential as novel therapeutic targets for AUD (Engel and
Jerlhag, 2014; Ray et al., 2014; Temko et al., 2017).
Among drugs with addictive properties, alcohol has some
unique characteristics, as it not only exerts pharmacological
actions in the central nervous system (CNS) and the periphery
but also has palatable properties and is a direct source of calories. In fact, previous research indicates considerable overlap
between biological processes involved in food craving, intake,
and metabolism and those that regulate alcohol-seeking and
consummatory behaviors (Volkow et al., 2012; Blanco-Gandía
et al., 2020). Notably, appetitive/metabolic hormones such as
ghrelin, leptin, glucagon-like peptide-1 (GLP-1), and insulin that

control homeostatic feeding and metabolism have also been
found to regulate hedonic and addictive properties of food and
alcohol, mainly through interactions with pathways related to
reward processing (van Zessen et al., 2012). In addition, several
lines of evidence suggest that stress-related pathways modulate both food and alcohol-seeking behaviors, primarily through
negative reinforcement mechanisms (Koob et al., 2014). The
hypothalamic-pituitary-adrenal (HPA) axis, a key neuroendocrine pathway involved in stress response, is directly activated
by alcohol at the pharmacological level (Zhou and Kreek, 2014).
Moreover, previous studies indicate that alterations in the HPA
axis may facilitate the transition from mild-to-moderate alcohol
drinking to AUD and may contribute to the risk of relapse (Koob,
2010; Blaine and Sinha, 2017). Based on the aforementioned
evidence, feeding- and stress-related endocrine pathways may
represent novel pharmacotherapeutic targets for AUD. One such
pathway is the ghrelin system, with growing evidence from preclinical and clinical studies supporting its role in biobehavioral
mechanisms underlying alcohol seeking and consumption
(Farokhnia et al., 2019b).
Ghrelin is a 28-amino acid peptide hormone primarily produced by enteroendocrine cells located in the oxyntic glands
of the stomach. A portion of the produced proghrelin undergoes acylation via the ghrelin-O-acyltransferase enzyme; the
acylated peptide is subsequently cleaved to form acyl-ghrelin.
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Background: Accumulating evidence has established a role for the orexigenic hormone ghrelin in alcohol-seeking behaviors.
Accordingly, the ghrelin system may represent a potential pharmacotherapeutic target for alcohol use disorder. Ghrelin
modulates several neuroendocrine pathways, such as appetitive, metabolic, and stress-related hormones, which are
particularly relevant in the context of alcohol use. The goal of the present study was to provide a comprehensive assessment
of neuroendocrine response to exogenous ghrelin administration, combined with alcohol, in heavy-drinking individuals.
Methods: This was a randomized, crossover, double-blind, placebo-controlled human laboratory study, which included 2
experimental alcohol administration paradigms: i.v. alcohol self-administration and i.v. alcohol clamp. Each paradigm
consisted of 2 counterbalanced sessions of i.v. ghrelin or placebo administration. Repeated blood samples were collected
during each session, and peripheral concentrations of the following hormones were measured: leptin, glucagon-like peptide-1,
pancreatic polypeptide, gastric inhibitory peptide, insulin, insulin-like growth factor-1, cortisol, prolactin, and aldosterone.
Results: Despite some statistical differences, findings were consistent across the 2 alcohol administration paradigms: i.v.
ghrelin, compared to placebo, increased blood concentrations of glucagon-like peptide-1, pancreatic polypeptide, cortisol, and
prolactin, both acutely and during the whole session. Lower levels of leptin and higher levels of aldosterone were also found
during the ghrelin vs placebo session.
Conclusion: These findings, gathered from a clinically relevant sample of heavy-drinking individuals with alcohol use
disorder, provide a deeper insight into the complex interplay between ghrelin and appetitive, metabolic, and stress-related
neuroendocrine pathways in the context of alcohol use.
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Methods
Setting and Participants
Data were collected under a human laboratory study conducted at the National Institutes of Health (NIH) Clinical Center

in Bethesda, Maryland. The protocol was approved by the NIH
Addictions Institutional Review Board (13-AA-0043), registered
at ClinicalTrials.gov (NCT01779024), and conducted under an
Investigational New Drug application (IND #117,778) following
review by the Food and Drug Administration. The primary goal of
the parent study was to examine the effects exogenous ghrelin
on i.v. alcohol self-administration and brain functional activity
in heavy alcohol drinkers (Farokhnia et al., 2018). Potential candidates were first screened through a phone interview, followed
by an in-person screening visit. Inclusion/exclusion criteria
were assessed, and eligible individuals were enrolled after providing written, informed consent. Enrolled participants were
non-treatment-seeking, heavy-drinking (>15 and >20 standard
drinks per week for females and males, respectively), alcoholdependent (DSM-IV-TR) individuals with no significant health
problems. For the complete list of eligibility criteria, see supplementary Appendix 1.

Design and Procedures
A detailed description of the parent study was previously reported (Farokhnia et al., 2018). Briefly, each participant underwent up to 4 experimental sessions (Figure 1): 2 i.v. alcohol
self-administration (IV-ASA) and 2 brain functional magnetic
resonance imaging (fMRI) sessions. The fMRI experiment included an i.v. alcohol clamp (IV-AC) designed to achieve a
target blood alcohol concentration. Alcohol administration
procedures were performed in accordance with the National
Institute on Alcohol Abuse and Alcoholism Council Guidelines
on Alcohol Administration (https://niaaa.nih.gov/Resources/
ResearchResources/job22.htm). Each experiment (IV-ASA and
IV-AC) had a crossover, randomized, double-blind, placebocontrolled design during which participants received a 10-minute loading dose of i.v. acyl-ghrelin (3 mcg/kg) or placebo,
followed by a continuous acyl-ghrelin (16.9 ng/kg/min) or
placebo infusion, until the end of each session. For more details about the experimental compounds, see supplementary
Appendix 2.
Intravenous Alcohol Self-Administration
During each 120-minute IV-ASA session, participants were
given the opportunity to self-administer alcohol via the
Computer-Alcohol Infusion System by pressing a button in
a progressive ratio manner. Each alcohol infusion was designed to increase the breath alcohol concentration (BrAC)
by 7.5 mg% over 2.5 minutes, with a subsequent decrease of
0.5 mg%/min, until the following infusion. Participants were
not allowed to administer alcohol beyond a maximum BrAC
of 120 mg%. Primary results of this paradigm showed that exogenous ghrelin administration, compared to placebo, significantly increased the total amount of alcohol self-administered
(Farokhnia et al., 2018).
Intravenous Alcohol Clamp
A predetermined dose of i.v. alcohol was administered as part
of a brain fMRI experiment. This alcohol infusion was designed
to increase the BrAC linearly to 80 mg% within 20 minutes and
maintain (clamp) the BrAC at this level for 15 minutes (therefore,
35 minutes in total). Primary results of this paradigm showed
that exogenous ghrelin, compared to placebo, differentially
modulated brain functional activity while anticipating alcohol
vs food reward (Farokhnia et al., 2018).
Participants were admitted to the NIH Clinical Center the
evening before each experimental session and were discharged
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Acyl-ghrelin has been termed the “active” form of ghrelin for
its ability to bind to and activate the growth hormone secretagogue receptor 1a (GHSR1a), also known as the ghrelin receptor
(Gahete et al., 2014). GHSR1a is a G protein-coupled receptor
widely expressed in both central (e.g., hypothalamus, pituitary,
ventral tegmental area, amygdala, hippocampus) and peripheral
(e.g., gut, pancreas, adipose tissue, adrenal gland, vagus nerve
terminals) tissues (Gnanapavan et al., 2002), mediating ghrelin’s
functions in the CNS and the periphery.
Ghrelin was first discovered to stimulate the release of growth
hormone (GH) from the pituitary through GHSR1a activation
(Kojima et al., 1999). Subsequent research has identified a wide
range of other key physiological functions, indicating that the
ghrelin system is critical for survival (Mani and Zigman, 2017).
Chiefly, ghrelin regulates both homeostatic and hedonic food intake (Perelló and Zigman, 2012; Yanagi et al., 2018). Ghrelin also
plays a major role in energy balance, as it regulates calorie intake
and expenditure and modulates key metabolic processes, such
as those involved in lipid and glucose homeostasis (Pradhan
et al., 2013; Lv et al., 2018; Gray et al., 2019). Growing evidence
suggests that ghrelin may also be considered a stress hormone,
as it closely interacts with biobehavioral pathways that regulate
stress response, for example, the HPA axis (Morris et al., 2018;
Stone et al., 2020). Accordingly, the ghrelin system has been extensively studied in relation to alcohol-related behaviors and is
currently under investigation as a potential therapeutic target for
AUD (Zallar et al., 2017; Farokhnia et al., 2019b; Lee et al., 2020).
Ghrelin’s effects on alcohol-related outcomes are thought
to be primarily driven through brain regions and neural circuits involved in reward processing, stress regulation, and cognition (Jerlhag et al., 2009; Meyer et al., 2014; Koob and Volkow,
2016). Peripherally secreted ghrelin is able to cross the bloodbrain barrier and binds to the GHSR1a in the CNS (Banks, 2012).
Another route through which ghrelin interacts with the brain
is vagal stimulation via activation of the GHSR1a expressed on
vagal afferent neurons (Dockray, 2013; Date, 2014; Tamboli et al.,
2017; Godlewski et al., 2019). Given the widespread presence of
ghrelin receptors in both central and peripheral tissues, ghrelin
signaling modulates a myriad of other neuroendocrine pathways, such as appetitive/metabolic and stress-related hormones.
These effects are particularly relevant in the context of alcohol
use, as neuroendocrine mechanisms may also be implicated in
the pathophysiology of AUD. In addition to a large body of preclinical evidence on the interaction between ghrelin, alcohol, and
neuroendocrine pathways, secondary analyses from a human laboratory study found reduced levels of leptin and insulin (HaassKoffler et al., 2015; Haass-Koffler et al., 2016) and increased levels
of cortisol and aldosterone (Haass-Koffler et al., 2019) following
i.v. administration of ghrelin in heavy-drinking individuals with
alcohol dependence. Of note, participants did not receive alcohol
in the aforementioned study (Leggio et al., 2014).
The goal of the present study was to provide a comprehensive
assessment of neuroendocrine response to a supraphysiological
pharmacological challenge with exogenous ghrelin by examining the effects on appetitive/metabolic and stress-related
endocrine outcomes in heavy-drinking individuals who also received i.v. alcohol under a controlled experimental setting.
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the morning after; therefore, each experimental session was conducted under a controlled inpatient setting, where parameters
such as alcohol intake, smoking breaks, and diet were closely
monitored and standardized. Three standardized meals and 1
standardized snack were served during each visit. A washout
period of at least 3 days was applied between study visits. For
additional details, see Figure 1 and supplementary Appendix 3.

Blood Collection, Processing, and Assays
Repeated blood samples (5 time-points; see Figure 1) were
obtained during each experimental visit via a saline lock
i.v. catheter that was fixed in the antecubital fossa of the
nondominant arm. Blood concentrations of the following
hormones were measured: total ghrelin, acyl-ghrelin, GH,
leptin, GLP-1, pancreatic polypeptide (PP), gastric inhibitory
peptide, insulin, insulin-like growth factor-1 (IGF-1), cortisol,
prolactin, and aldosterone. Details regarding blood collection, processing, and assays are presented in supplementary
Appendix 4. Values below the lower limit of quantitation
(LLOQ) for each assay were set to 1/2 of the LLOQ (Keizer et al.,
2015).

Statistical Methods
Demographic characteristics of the study sample were summarized with descriptive statistics (mean and standard error for continuous variables, number and percent for categorical variables).
Data from the ghrelin sessions of the IV-ASA and IV-AC were used
to characterize kinetic parameters of peripheral acyl-ghrelin and
total ghrelin concentrations in this study. Noncompartmental
analyses were run, and the linear trapezoidal rule was applied
for estimations (Phoenix WinNonlin, Pharsight Corp., version
6.3; Mountain View, CA). Calculated parameters included area
under the plasma concentration-time curve (AUC0-last), maximum
plasma concentration (Cmax), time of Cmax (Tmax), half-life, mean
residence time (MRT), clearance (Cl), and volume of distribution
(Vd). Baseline correction was performed using pre-dose concentrations of the placebo session. This correction was done to minimize the within-day variability of each hormone and to provide
a more accurate estimation of acyl-ghrelin and total ghrelin kinetic parameters (Scheff et al., 2011). Neuroendocrine outcomes
were first tested for statistical outliers and normal distribution.
Leptin, GLP-1, and GH data for the IV-ASA experiment and acylghrelin and total ghrelin data for the IV-AC experiment were
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Figure 1. Schematic outline of the events and blood sampling time-points during (A) i.v. alcohol self-administration (IV-ASA) experiment (2 visits), and (B) i.v. alcohol
clamp (IV-AC) experiment (2 visits). Each participant underwent up to 4 experimental sessions. During each session, a 10-minute loading dose of i.v. acyl-ghrelin (3 mcg/
kg) or placebo was administered, followed by a continuous infusion of acyl-ghrelin (16.9 ng/kg/min) or placebo until the end of the session.
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Results
Sample Characteristics and Ghrelin Concentrations
Of 77 individuals screened, 18 signed the informed consent and were
enrolled. A final sample of 11 and 8 participants completed both
IV-ASA sessions and both IV-AC sessions, respectively, and were included in the analyses (supplementary Figure 1). Table 1 summarizes
the demographic characteristics of the study sample. Enrolled participants were predominantly male and African American. Although
not a required eligibility criterion, all participants had a current diagnosis of alcohol dependence based on DSM-IV-TR.
As expected, i.v. ghrelin administration significantly increased blood concentrations of acyl-ghrelin, total ghrelin, and
GH (see supplementary Figures 2 and 3), confirming that the
supraphysiological challenge with exogenous acyl-ghrelin was
successful (i.e., ghrelin levels increased) and pharmacologically effective (i.e., GH levels increased). Ten individuals from the IV-ASA

experiment and 6 individuals from the IV-AC experiment had
complete data for calculation of acyl-ghrelin and total ghrelin kinetic parameters (supplementary Tables 1 and 2). Respective spaghetti plots are also depicted in supplementary Figures 4 and 5.

Neuroendocrine Outcomes
Intravenous Alcohol Self-Administration Experiment
Figure 2 outlines the IV-ASA experiment neuroendocrine outcomes.
Baseline (T0) concentrations of the measured hormones did
not significantly differ between the 2 IV-ASA sessions, except
for significantly higher baseline insulin levels prior to i.v. ghrelin
than placebo administration (supplementary Table 3).
Comparison of change (Δ) from T0 to T1 showed that IV
ghrelin, compared to placebo, significantly increased blood
concentrations of GLP-1 (t [20] = −4.91, P < .001), PP (t [20] = −5.27,
P < .001), cortisol (t [19] = −4.65, P < .001), and prolactin (t
[18] = −4.56, P < .001) (Figure 2; Table 2).
Analysis of repeated measures during the IV-ASA experiment (T1, T2, T3, and T4) after controlling for baseline (T0)
found lower leptin (F [1, 57.78] = 6.28, P = .01) and higher GLP-1
(F [1, 55.28] = 75.73, P < .001), PP (F [1, 61.11] = 55.56, P < .001), insulin (F [1, 50.75] = 21.85, P < .001), cortisol (F [1, 63.34] = 186.75,
P < .001), prolactin (F [1, 59.93] = 87.45, P < .001), and aldosterone (F
[1, 65.63] = 15.62, P < .001) concentrations under i.v. ghrelin compared to placebo, as indicated by significant drug main effects.
Significant drug × time-point interaction effects were also found
for PP (F [3, 61.65] = 5.71, P = .002) and prolactin (F [3, 53.39] = 5.65,
P = .002) (Figure 2; Table 3). Of note, the significant drug main effect on insulin appears to be a carryover effect of significantly
higher levels of insulin at baseline, that is, prior to ghrelin vs
placebo administration (Figure 2E).
Intravenous Alcohol Clamp Experiment
Figure 3 outlines the IV-AC experiment neuroendocrine outcomes. Baseline (T0) concentrations of the measured hormones
did not significantly differ between the 2 IV-AC sessions (supplementary Table 4).
Comparison of change (Δ) from T0 to T1 showed that i.v.
ghrelin, compared to placebo, significantly increased blood concentrations GLP-1 (t [11] = −4.67, P = .001), cortisol (t [11] = −4.76,
P = .001), and prolactin (t [10] = −4.96, P = .001); a trend-level increase in PP (t [10] = −1.85, P = .06) was also found (Figure 3; Table 4).

Table 1. Demographic Characteristics of the Study Sample
IV-ASA experiment
(n = 11)
Age, years, M (SEM)
Gender, males, n (%)
Race, African Americans, n (%)
Education, years, M (SEM)
Annual incomea, n (%)
Below average
Average
Above average
Body weight, kg, M (SEM)
BMI, kg/m2, M (SEM)
Family history density of problem drinkingb, M (SEM)
Current cigarette smoker, n (%)

IV-AC experiment
(n = 8)

39.86 (3.54)
8 (72.72)
9 (81.81)
13.36 (0.49)

42.50 (3.12)
6 (75)
7 (87.5)
13.75 (0.70)

7 (63.63)
3 (27.27)
1 (9.09)
77.44 (3.29)
25.42 (0.87)
0.10 (0.03)
8 (72.72)

5 (62.5)
2 (25)
1 (12.5)
77.90 (3.50)
25.88 (0.98)
0.14 (0.05)
5 (62.5)

Abbreviations: BMI, body mass index; IV-AC, intravenous alcohol clamp; IV-ASA, intravenous alcohol self-administration; M, mean; SEM, standard error of the mean.
aBelow average: <$30 000; average: $30 000-$49 000; above average: ≥$50 000.
bBased on Family Tree Questionnaire: density of relatives (siblings, parents, grandparents) with definite problem drinking (self-reported).

Downloaded from https://academic.oup.com/ijnp/article/24/6/464/6131742 by guest on 02 May 2022

not normally distributed and therefore were log10 transformed,
which led to significant improvement in normality. Baseline (T0)
concentrations of the endocrine outcomes were compared between the 2 sessions (i.v. ghrelin vs placebo) of each experiment
using independent samples t test. To examine i.v. ghrelin’s acute
effect, we first compared the change (Δ) in blood concentrations
of each neuroendocrine outcome from baseline (T0) to post-drug
(T1) in response to i.v. ghrelin vs placebo using independent samples t test. Next, we examined the pattern/time course of these
hormones over a longer timeframe, that is, during the i.v. ghrelin
vs placebo sessions. For this purpose, repeated measurements of
each neuroendocrine outcome were analyzed via linear mixedeffects models with drug condition (i.v. ghrelin, placebo), blood
sampling time-point (T1, T2, T3, T4), and drug × time-point interaction as fixed effects, individual participants as a random effect,
and blood concentrations of each hormone as the outcome. Age,
gender, body weight, session order (i.v. ghrelin or placebo first),
total number of alcohol infusions self-administered (IV-ASA experiment only), and baseline (T0) concentration of each hormone
(first time-point) were also included as covariates. Partial eta
squared (η 2p) values were also calculated to indicate effect sizes.
Analyses were performed using the Statistical Package for the
Social Sciences (SPSS) software (IBM Corp., version 25; Armonk,
NY), and significance level was set at P < .05 (2-tailed).
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Figure 2. Blood concentrations of neuroendocrine outcomes during ghrelin and placebo sessions of the i.v. alcohol self-administration (IV-ASA) experiment. A 10-minute
loading dose of i.v. acyl-ghrelin (3 mcg/kg) or placebo was administered, followed by a continuous infusion of acyl-ghrelin (16.9 ng/kg/min) or placebo until the end of
each session. Alcohol self-administration started simultaneously with the ghrelin/placebo continuous infusion (between T0 and T1) and continued until the end of the
session (T4). T0: 25 minutes before the start of the ghrelin/placebo loading dose; T1: 30 minutes after the start of the ghrelin/placebo continuous infusion; T2: 60 minutes
after the start of the ghrelin/placebo continuous infusion; T3: 90 minutes after the start of the ghrelin/placebo continuous infusion; T4: 120 minutes after the start of
the ghrelin/placebo continuous infusion. Blood concentrations of each hormone per time-point are expressed as mean (M) and standard error of the mean (SEM). For
statistical results, see Table 2. Abbreviations: GIP, gastric inhibitory peptide; GLP-1, glucagon-like peptide-1; IGF-1, insulin-like growth factor-1; PP, pancreatic polypeptide.

Analysis of repeated measures during the IV-ASA experiment
(T1, T2, T3, and T4) after controlling for baseline (T0) found lower
IGF-1 (F [1, 19.35] = 5.29, P = .03) and higher GLP-1 (F [1, 31.53] = 30.40,
P < .001), PP (F [1, 36.00] = 17.47, P < .001), cortisol (F [1, 22.66] = 42.53,
P < .001), prolactin (F [1, 33.37] = 134.14, P < .001), and aldosterone (F
[1, 30.15] = 36.44, P < .001) concentrations under i.v. ghrelin, compared to placebo, as indicated by significant drug main effects.
A significant drug × time-point interaction effect was also found
for cortisol (F [3, 33.55] = 3.34, P = .03) (Figure 3; Table 5). Of note,
the significant drug main effect on IGF-1 appears to be driven
by an unexpected increase in IGF-1 concentrations at T3 and T4
under the placebo condition (Figure 3F).

Discussion
The present study investigated the effects of a supraphysiological
challenge with exogenous ghrelin on peripheral concentrations
of a range of hormones in heavy-drinking, alcohol-dependent

individuals concurrently receiving i.v. alcohol. Despite methodological differences in terms of alcohol dosage, blood sampling time-points, etc., the results were in overall agreement
and internally replicated across the 2 alcohol administration
paradigms (i.e., IV-ASA and IV-AC). i.v. ghrelin, compared to placebo, significantly increased blood concentrations of GLP-1, PP,
cortisol, and prolactin both acutely (Δ T0-T1) and during the session (T1, T2, T3, and T4, while controlling for T0). Lower levels of
leptin and higher levels of aldosterone were also found during
the ghrelin vs placebo session (Figure 4).
In addition to the supraphysiological challenge with exogenous ghrelin, the experiments in this study included i.v. administration of alcohol using a well-established computer-based
method that limited the variability in alcohol levels/exposure
typically observed after oral alcohol consumption (Cyders et al.,
2020). The 2 experimental paradigms (IV-ASA and IV-AC) could
be considered complementary, as they included different levels
and durations of exposure to alcohol as well as different blood
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Table 2. Comparison of Change in Blood Concentrations of Neuroendocrine Outcomes, From Baseline to Post-Drug Time-Pointa, Between
Placebo and Ghrelin Sessions of the IV-ASA Experiment

Δ Leptin (Log10) concentration (pg/mL)
Δ GLP-1 (Log10) concentration (pg/mL)
Δ PP concentration (pg/mL)
Δ GIP concentration (pg/mL)
Δ Insulin concentration (pg/mL)
Δ IGF-1 concentration (ng/mL)
Δ Cortisol concentration (mcg/dL)
Δ Prolactin concentration (ng/mL)
Δ Aldosterone concentration (pg/mL)

Placebo session, M (SEM)

Ghrelin session, M (SEM)

Independent samples t test

−0.11 (0.02)
−0.32 (0.04)
−221.46 (28.44)
−151.94 (51.00)
−81.95 (39.32)
−4.63 (4.94)
−3.15 (1.14)
−0.13 (0.78)
−44.41 (18.31)

−0.09 (0.02)
0.16 (0.08)
−43.87 (18.01)
−68.62 (79.23)
−84.42 (144.79)
1.28 (4.19)
6.24 (1.70)
12.74 (2.70)
18.07 (33.49)

t (18) = −0.62, P = .54
t (20) = −4.91, P < .001
t (20) = −5.27, P < .001
t (20) = −0.88, P = .38
t (18) = 0.01, P = .98
t (20) = −0.91, P = .37
t (19) = −4.65, P < .001
t (18) = −4.56, P < .001
t (19) = −1.67, P = .11

Table 3. Drug, Time-Point, and Drug × Time-Point Effects on Neuroendocrine Outcomes During the IV-ASA Experiment

Leptin
GLP-1
PP
GIP
Insulin
IGF-1
Cortisol
Prolactin
Aldosterone

Druga main effect

Time-pointb main effect

Drug × time-point interaction effect

F (1, 57.78) = 6.28, P = .01
η 2p = 0.09
F (1, 55.28) = 75.73, P < .001
η 2p = 0.57
F (1, 61.11) = 55.56, P < .001
η 2p = 0.47
F (1, 66.97) = 3.66, P = .06
η 2p = 0.05
F (1, 50.75) = 21.85, P < .001
η 2p = 0.30
F (1, 60.68) = 0.11, P = .73
η 2p = 0.001
F (1, 63.34) = 186.75, P < .001
η 2p = 0.74
F (1, 59.93) = 87.45, P < .001
η 2p = 0.59
F (1, 65.63) = 15.62, P < .001
η 2p = 0.19

F (3, 55.38) = 5.26, P = .003
η 2p = 0.22
F (3, 59.24) = 20.43, P < .001
η 2p = 0.50
F (3, 61.65) = 14.45, P < .001
η 2p = 0.41
F (3, 60.30) = 25.61, P < .001
η 2p = 0.56
F (3, 46.58) = 12.36, P < .001
η 2p = 0.44
F (3, 60.18) = 0.29, P = .82
η 2p = 0.01
F (3, 57.40) = 3.60, P = .01
η 2p = 0.15
F (3, 53.40) = 15.06, P < .001
η 2p = 0.45
F (3, 59.20) = 2.61, P = .05
η 2p = 0.11

F (3, 55.38) = 0.03, P = .99
η 2p = 0.002
F (3, 59.38) = 1.75, P = .16
η 2p = 0.08
F (3, 61.65) = 5.71, P = .002
η 2p = 0.21
F (3, 60.30) = 1.63, P = .19
η 2p = 0.07
F (3, 46.58) = 2.15, P = .10
η 2p = 0.12
F (3, 60.21) = 1.05, P = .37
η 2p = 0.05
F (3, 57.40) = 0.70, P = .55
η 2p = 0.03
F (3, 53.39) = 5.65, P = .002
η 2p = 0.24
F (3, 59.20) = 1.73, P = .17
η 2p = 0.08

Abbreviations: GIP, gastric inhibitory peptide; GLP-1, glucagon-like peptide-1; IGF-1, insulin-like growth factor-1; IV-ASA, i.v. alcohol self-administration; PP, pancreatic
polypeptide.
aIntravenous ghrelin or placebo.
bT1 (30 minutes after the start of the ghrelin/placebo continuous infusion), T2 (60 minutes after the start of the ghrelin/placebo continuous infusion), T3 (90 minutes
after the start of the ghrelin/placebo continuous infusion), and T4 (120 minutes after the start of the ghrelin/placebo continuous infusion). T0 (baseline) was included
as a covariate in each model, along with age, gender, body weight, session order, and total number of alcohol infusions self-administered. See Figure 1 for more details.

sampling time-points in relation to both i.v. ghrelin and alcohol
administration (see Figure 1). Specifically, the IV-ASA experiment had a longer duration, included a variable dose of alcohol
(proportionate to the amount that each participant decided to
self-administer), and all sampling time-points occurred under
i.v. ghrelin (or i.v. placebo) plus alcohol. On the other hand, the
IV-AC had a shorter duration, included a predetermined dose
of alcohol (designed to achieve a target blood alcohol concentration), and had 1 sampling time-point (T1) that occurred
under only i.v. ghrelin (or i.v. placebo) infusion, before alcohol
administration began, hence providing an opportunity to relatively tease out the effects of “ghrelin” per se vs “ghrelin plus
alcohol.” Nonetheless, our observations are consistent with
previous work on endocrine response to exogenous ghrelin
administration (for review, see Garin et al., 2013b) and provide
novel information among a clinically relevant population (i.e.,

heavy-drinking individuals with alcohol dependence) and in
the context of alcohol use, which is also a major modulator of
peripheral and central endocrine pathways.
A large body of preclinical and clinical evidence indicates
that peripheral leptin levels are associated with biobehavioral
correlates of alcohol craving, use, and withdrawal (Bach et al.,
2020). Results of the present study are comparable with our
previous finding of exogenous ghrelin-induced reduction in
circulating leptin levels in heavy-drinking individuals with alcohol dependence in a cue-reactivity study without actual alcohol administration (Haass-Koffler et al., 2015). Ghrelin and
leptin have inverse functions in relation to appetite, food intake, metabolism, and alcohol use, and it has been suggested
that leptin negatively mediates peripheral ghrelin levels (Klok
et al., 2007; Nogueiras et al., 2008). It is important to note that
although leptin levels were lower under ghrelin, compared to
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Abbreviations: GIP, gastric inhibitory peptide; GLP-1, glucagon-like peptide-1; IGF-1, insulin-like growth factor-1; IV-ASA, i.v. alcohol self-administration; M, mean; PP,
pancreatic polypeptide; SEM, standard error of the mean.
aBaseline (T0): 25 minutes before the start of the ghrelin/placebo loading dose, post-drug (T1): 30 minutes after the start of the ghrelin/placebo continuous infusion.
See Figure 1 for more details.
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Figure 3. Blood concentrations of neuroendocrine outcomes during ghrelin and placebo sessions of the i.v. alcohol clamp (IV-AC) experiment. A 10-minute loading dose
of i.v. acyl-ghrelin (3 mcg/kg) or placebo was administered, followed by a continuous infusion of acyl-ghrelin (16.9 ng/kg/min) or placebo until the end of each session.
Alcohol clamp started at T2 and continued until the end of the session (5 minutes before T4). T0: 5 minutes before the start of the ghrelin/placebo loading dose; T1: at
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placebo, during both IV-ASA and IV-AC experiments (Figures 2A
and 3A), the difference did not reach statistical significance for
the IV-AC experiment. In general, due to inherent limitations
of the present study (e.g., small sample size, inter-individual
variability, secondary nature of the analyses), we encourage the
readers to focus more on the pattern and direction of hormonal
changes (depicted in Figures 2–4) rather than pure statistical results (presented in Tables 2–5). This approach is consistent with
the overall goal of the present study, that is, to evaluate how
these hormones “behave” in response to and under i.v. ghrelin,
compared to placebo, in the context of alcohol use.
Akin to the data presented here (Figures 2B and 3B), studies
in both rodents and humans have observed an increase in
GLP-1 concentrations following ghrelin administration (Tong
et al., 2016; Lindqvist et al., 2017). GLP-1 is an incretin produced mainly by L-cells of the intestinal mucosa and plays a
key role in regulating food intake and glucose homeostasis
(Müller et al., 2019). While some studies suggest that ghrelin’s

effect on GLP-1 production and secretion might be driven by
direct actions on intestinal L-cells, others do not confirm such a
direct interaction (Jepsen et al., 2019). It appears that the crosstalk between insulinostatic ghrelin and insulinotropic GLP-1 is
largely mediated through indirect glucose-dependent mechanisms (Djurhuus et al., 2002; Damdindorj et al., 2012; Page
et al., 2018), although the exact molecular mechanism remains
unknown. Preclinical studies have suggested that ghrelin and
GLP-1 signaling may overlap in the nucleus accumbens to regulate alcohol intake and reward (Abtahi et al., 2018). Therefore,
targeting these endocrine pathways offers potential novel treatment options for individuals with AUD (Farokhnia et al., 2019b;
Jerlhag, 2020). In a previous cue-reactivity study with i.v. ghrelin,
we found different results for insulin and GLP-1. Specifically, i.v.
ghrelin reduced blood insulin levels without significantly affecting GLP-1 levels (Haass-Koffler et al., 2016). Together, these
findings suggest that unlike other hormones investigated here
(e.g., leptin, cortisol, and aldosterone, for which we did replicate
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Table 4. Comparison of Change in Blood Concentrations of Neuroendocrine Outcomes, From Baseline to Post-Drug Time-Pointa, Between Placebo and Ghrelin Sessions of the IV-AC Experiment

Δ Leptin Concentration (pg/mL)
Δ GLP-1 Concentration (pg/mL)
Δ PP Concentration (pg/mL)
Δ GIP Concentration (pg/mL)
Δ Insulin Concentration (pg/mL)
Δ IGF-1 Concentration (ng/mL)
Δ Cortisol Concentration (mcg/dL)
Δ Prolactin Concentration (ng/mL)
Δ Aldosterone Concentration (pg/mL)

Placebo session, M (SEM)

Ghrelin session, M (SEM)

65.79 (145.13)
−3.77 (1.64)
−36.07 (30.36)
45.58 (47.83)
47.67 (57.69)
−5.06 (3.77)
−0.26 (0.72)
−0.23 (0.24)
2.43 (6.97)

102.95 (175.28)
13.81 (3.16)
197.86 (102.96)
64.36 (38.40)
−26.45 (87.58)
−5.47 (8.43)
6.91 (1.24)
9.73 (1.99)
35.51 (30.35)

Independent samples t Test
t (11) = −0.16, P = 87
t (11) = −4.67, P = 001
t (10) = −1.85, P = 06
t (11) = −0.31, P = 76
t (11) = 0.68, P = 51
t (11) = 0.04, P = 96
t (11) = −4.76, P = 001
t (10) = −4.96, P = 001
t (9) = −0.96, P = 35

Table 5. Drug, Time-Point, and Drug × Time-Point Effects on Neuroendocrine Outcomes During the IV-AC Experiment
Druga main effect
Leptin
GLP-1
PP
GIP
Insulin
IGF-1
Cortisol
Prolactin
Aldosterone

F (1, 8.58) = 0.19, P = .67
η 2p = 0.02
F (1, 31.53) = 30.40, P < .001
η 2p = 0.49
F (1, 36.00) = 17.47, P < .001
η 2p = 0.32
F (1, 37.00) = 0.01, P = .90
η 2p = 0.0004
F (1, 19.75) = 0.67, P = .42
η 2p = 0.03
F (1, 19.35) = 5.29, P = .03
η 2p = 0.21
F (1, 22.66) = 42.53, P < .001
η 2p = 0.65
F (1, 33.37) = 134.14, P < .001
η 2p = 0.80
F (1, 30.15) = 36.44, P < .001
η 2p = 0.54

Time-pointb main effect

Drug × time-point interaction effect

F (3, 35.04) = 0.44, P = .72
η 2p = 0.03
F (3, 35.07) = 6.36, P = .001
η 2p = 0.35
F (3, 36.00) = 7.42, P = .001
η 2p = 0.38
F (3, 37.00) = 2.44, P = .08
η 2p = 0.16
F (3, 31.45) = 13.36, P < .001
η 2p = 0.56
F (3, 34.24) = 0.31, P = .81
η 2p = 0.02
F (3, 33.55) = 4.32, P = .01
η 2p = 0.27
F (3, 32.66) = 1.02, P = 0.39
η 2p = 0.08
F (3, 28.88) = 0.68, P = .56
η 2p = 0.06

F (3, 35.06) = 0.97, P = .41
η 2p = 0.07
F (3, 35.07) = 0.85, P = .47
η 2p = 0.06
F (3. 36.00) = 1.59, P = .20
η 2p = 0.11
F (3, 37.00) = 0.57, P = .63
η 2p = 0.04
F (3, 31.45) = 0.41, P = .74
η 2p = 0.03
F (3, 34.24) = 0.88, P = .46
η 2p = 0.07
F (3, 33.55) = 3.34, P = .03
η 2p = 0.23
F (3, 32.62) = 0.50, P = .68
η 2p = 0.04
F (3, 28.88) = 1.20, P = .32
η 2p = 0.11

Abbreviations: GIP, gastric inhibitory peptide; GLP-1, glucagon-like peptide-1; IGF-1, insulin-like growth factor-1; IV-AC, i.v. alcohol clamp; PP, pancreatic polypeptide.
aIntravenous ghrelin and placebo
bT1 (at the end of the ghrelin/placebo loading dose and the start of the ghrelin/placebo continuous infusion), T2 (30 minutes after the start of the ghrelin/placebo
continuous infusion), T3 (45 minutes after the start of the ghrelin/placebo continuous infusion), and T4 (70 minutes after the start of the ghrelin/placebo continuous
infusion). T0 (baseline) was included as a covariate in each model, along with age, gender, body weight, and session order. See Figure 1 for more details.

our previous findings), the crosstalk between ghrelin and hormones such as insulin and GLP-1 may be more subject to variability and sensitive to different experimental conditions and
settings. For example, in the previous study, there was no alcohol coadministration, fasting conditions differed, and the
overall design was quite different.
Exogenous ghrelin administration, compared to placebo,
had a robust effect on PP levels in this study. PP is a 36-amino
acid polypeptide produced by PP cells of pancreatic islets (islets
of Langerhans). PP is involved in self-regulation of endocrine
and exocrine functions of the pancreas and acts primarily as
an anorexigenic hormone by suppressing food intake, delaying
gastric emptying, and increasing energy expenditure (Lonovics
et al., 1981). PP has been suggested to be a biomarker of vagal
activity (Schwartz, 1983b). While alcohol has been shown to decrease PP (Sehested et al., 1998), ghrelin has been found to increase PP levels (Arosio et al., 2003). In this study, it is likely that
i.v. ghrelin administration initially increased serum PP levels,

but this stimulatory effect was blunted by administration of alcohol. This interpretation is supported by comparing the PP results during the IV-ASA vs IV-AC experiments, as the variation
in timing of i.v. ghrelin and alcohol administration between the
studies shows a distinct stimulatory effect of ghrelin and inhibitory effect of alcohol on PP. In other words, the interval between
T0 and T1 of the IV-AC experiment, when only i.v. ghrelin (and
no i.v. alcohol) is on board, revealed a clear separation where i.v.
ghrelin increased PP concentrations (Figure 3C). Consistent with
this observation, during the IV-ASA experiment, which did not
include an alcohol-free blood sampling time-point, exogenous
ghrelin administration, compared to placebo, clearly blunted
the alcohol-induced reduction in PP concentrations, which even
resulted in a significant drug × time-point interaction (Figure
2C). Given that the secretion of PP is tightly regulated by vagal
cholinergic mechanisms (Schwartz, 1983a) and ghrelin receptors are widely expressed in the vagal afferent neurons (Date,
2012), changes in PP concentrations in response to exogenous
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Abbreviations: GIP, gastric inhibitory peptide; GLP-1, glucagon-like peptide-1; IGF-1, insulin-like growth factor-1; IV-AC, i.v. alcohol clamp; M, mean; PP, pancreatic polypeptide; SEM, standard error of the mean.
aBaseline (T0): 5 minutes before the start of the ghrelin/placebo loading dose, post-drug (T1): at the end of the ghrelin/placebo loading dose and the start of the
ghrelin/placebo continuous infusion. See Figure 1 for more details.
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Figure 4. A graphical summary of the main hormonal changes, found in this
study, in response to i.v. ghrelin, compared to placebo. Findings were in overall
agreement across the 2 alcohol administration paradigms (i.e., IV-ASA and
IV-AC). Increased levels of growth hormone, prolactin, cortisol, aldosterone, pancreatic polypeptide, and glucagon-like peptide-1, and decreased levels of leptin
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ghrelin administration can be interpreted as a proxy of GHSR1a activity on vagal dendrites in the periphery. Accordingly,
peripheral activation of vagal GHS-R1a has been proposed as a
main route carrying the ghrelin signal to the CNS (Dockray, 2013;
Date, 2014; Tamboli et al., 2017). Of note, we previously reported
that exogenous ghrelin administration significantly reduced
systolic and diastolic blood pressure in this (Farokhnia et al.,
2018) and previous (Leggio et al., 2014) work, which is consistent
with other reports on GHSR1a-dependent autonomic activity of
ghrelin (Garin et al., 2013a; Zhang et al., 2017).
Consistent with our findings, several preclinical and clinical studies have found that ghrelin stimulates the production and/or secretion of cortisol, aldosterone, and prolactin,
leading to increased concentrations of these hormones in the
periphery (Arvat et al., 2001; Vestergaard et al., 2007; Messini
et al., 2011; Zhang et al., 2017; Haass-Koffler et al., 2019;
Akalu et al., 2020). Ghrelin-knockout models in rodents have
identified the centrally projecting Edinger-Wesphal nucleus,
specifically urocortin 1 neurons, as a link between GHS-R1a
activation and corticosterone response (Spencer et al., 2012).
Furthermore, GHS-R1a is expressed throughout the CNS, most
notably in the hypothalamus pituitary unit, and ghrelin has
been found to increase corticotropin-releasing factor mRNA
in hypothalamic 4b cells in vitro (Gnanapavan et al., 2002;
Shuto et al., 2002; Kageyama et al., 2012). The higher concentrations of aldosterone under i.v. ghrelin, compared to placebo, observed in this study (Figures 2I and 3I) are consistent
with previous clinical (Zhang et al., 2017; Haass-Koffler et al.,
2019) and preclinical (Andreis et al., 2003; Milosević et al.,
2010; Rucinski et al., 2012) reports that ghrelin-induced activation of the HPA axis extends to both glucocorticoids and mineralocorticoids and that manipulation of the ghrelin system
has a global stimulatory effect on the adrenal cortex. The

precise mechanism of ghrelin-induced increases in prolactin
levels remains unclear, although some evidence suggests a
mechanistic pairing of GHS-R1a activity and prolactin secretion (Rubinfeld et al., 2004). Together, the established GH response, adrenocorticotropic hormone secretion, and evidence
of prolactin release point to ghrelin as a strong pituitary releasing agent. Of note, prolactin has been suggested to be a
neuromodulator of extrahypothalamic dopaminergic activity
(Hernández et al., 1994), and alcohol has also been found to
modulate peripheral prolactin levels (Frias et al., 2000).
The present study had several strengths and limitations.
The sample had a relatively small size and was limited to
heavy-drinking individuals with alcohol dependence. The strict
inclusionary and exclusionary criteria for enrollment (supplementary Appendix 1) resulted in a homogenous sample of participants, thus reducing random variability in our measures
and analyses. However, this factor limits the generalizability
of our findings. As a human laboratory study, the experimental
settings (e.g., drug dosage, meals, blood sampling time-points)
were strictly controlled before and during each experiment.
Although such a design provides a rigorous research platform,
it may not reflect a real-world condition and the results may
not be generalizable to other settings. Two different, yet complementary, i.v. alcohol administration paradigms (IV-ASA
and IV-AC) were employed, and the results were internally
replicated with some statistical differences across the 2 paradigms. Application of i.v. alcohol minimizes variation in alcohol
pharmacokinetics and is therefore suitable for such studies, but
this route bypasses the gastrointestinal tract and the hepatic
first pass metabolism, factors that may influence at least some
of the neuroendocrine outcomes investigated here. Given the
secondary nature of this study, inter-individual variability, and
small sample size, we were not able to analyze possible clinical/
behavioral correlates of the observed neuroendocrine effects
in response to exogenous ghrelin administration—a relevant
question that should be investigated in future studies with a
larger sample and an a priori design for this purpose. Another
limitation is that glucose levels were not measured during the
experiments. Given that ghrelin plays an important role in glucose regulation, whether the effects of exogenous ghrelin on
glucose-regulating hormones (e.g., GLP-1) are dependent on, or
independent of, glucose levels remains unanswered. Finally, we
had a placebo session to be compared to the i.v. ghrelin condition, but i.v. alcohol was not matched with a control and participants received alcohol during all sessions, because of the
design of the parent study. The effects of the supraphysiological
challenge with ghrelin on neuroendocrine outcomes appeared
to surpass the effects of alcohol, at least with the doses used in
this study. That said, disentangling the effects of ghrelin vs alcohol would require a fully factorial 2 (i.v. ghrelin vs placebo) × 2
(i.v. alcohol vs control) design.
In conclusion, the findings of the present study, gathered
from a clinically relevant sample of heavy-drinking individuals with alcohol dependence, provide a deeper insight into the
complex interplay between ghrelin and appetitive, metabolic,
and stress-related endocrine pathways in the context of alcohol
use. More studies are required to understand the mechanisms
underlying these effects and their potential direct and/or indirect relevance to alcohol-related behaviors.

Supplementary Materials
Supplementary data are available at International Journal of
Neuropsychopharmacology (IJNPPY) online.
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